This Pandemic Stock Has Just Begun to Push Higher

0
369

Keep an eye on Altimmmune Inc. (ALT).

The stock is pushing higher thanks to more positive data on its COVID candidate.

The company just published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID, adding the candidate “stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract.”

“AdCOVID is designed to offer significant advantages over other COVID-19 vaccine approaches, including intranasal administration, single-dose effectiveness, broad activation of the immune response, and the ability to ship and store the vaccine conveniently and inexpensively,” according to the company.